Piramal Pharma opened lower at ₹196.40, compared with its previous close of ₹196.66. During today's session, the stock has traded between ₹191.41 and ₹197.00, with an average traded price of ₹194.20. It is currently showing a sideways intraday trend.
An investment of ₹10,000 made 4 years ago in Piramal Pharma is now worth
₹ 10,564.00
giving a profit of
₹ 564.00 (5.64%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
-0.65 (-0.33%)
Day High
₹197.00
Day Low
₹191.41
Day Open
₹196.40
Prev Close
₹196.66
Volume
13,90,936
Value Traded
₹27.01 Cr
1W Return
0.57%
1M Return
-7.26%
3M Return
10.64%
6M Return
34.27%
1Y Return
-2.82%
Market Cap (₹ Cr.)
26,096
PE Ratio
-83.20
PB Ratio
3.20
Dividend Yield
0.07%
ROE
-3.99%
ROCE
1.25%
Book Value (₹)
61.34
Face Value (₹)
10.00
EPS (TTM)
-0.52
Industry PE
-
Beta
-
Debt to Equity
-
1 Week
0.57%
6 Week
-
1 Month
-7.26%
3 Month
10.64%
9 Month
16.86%
Piramal Pharma's sales deal with Bayer ends December 31, 2026
Piramal Pharma's sales deal with Bayer Pharmaceuticals will not be renewed. The agreement is set to expire on December 31, 2026. No renewal of the commercial sales arrangement has been indicated.
12 days agoPiramal Pharma receives ₹4.06 crore GST demand and penalty for FY21-FY23
Received GST demand of ₹4.06 crore and equivalent penalty for FY21-FY23. Order issued by Mumbai East Commissionerate on September 28, 2026. Dispute centers on input tax credits during post-demerger transition. Company plans to appeal, asserting no material impact on financials.
14 days agoPiramal Pharma's Morpeth facility receives seven US FDA observations
Piramal Pharma's Morpeth facility received seven observations from the US FDA following an inspection. US FDA observations are issued via Form 483 and indicate areas of potential regulatory concern at the inspected site. Companies are typically required to respond to such observations with corrective and preventive action plans.
28 days agoPiramal Pharma hosts institutional investor meetings in UK
Piramal Pharma to hold investor meets in UK on Sep 29-30, 2026. Meetings organized by Avendus Spark Institutional Equities. Format includes physical group and one-on-one sessions. Schedule disclosed under SEBI LODR Regulation 30(6).
1mo agoDeutsche Bank re-pledges 98.4M Piramal Pharma shares
Deutsche Bank re-pledged 98.4M Piramal Pharma shares (7.39% stake). Total encumbrance restored to 238.66M shares (17.93% stake). Move follows temporary release for permitted sale transaction. Borrower is CA Alchemy Investments; lenders include Barclays and Nomura.
1mo agoPiramal Pharma reports 22.6% drop in Scope 1 & 2 emissions for FY26
Scope 1 & 2 emissions fell 22.6% vs FY22 baseline. Revenue declined to ₹8,869 crore from ₹9,151 crore. Net loss widened to ₹325.94 crore from profit of ₹91.13 crore. Renewable energy met 41% of total consumption. Zero data breaches and zero fatalities reported.
1mo ago| Stock | LTP | Change % | Market Cap (Cr.) | PE | 1Y Return |
|---|---|---|---|---|---|
| ₹1,770.70 | +0.61% | ₹4,24,850.24 | 34.83 | +5.97% | |
| ₹9,285.00 | -1.50% | ₹2,46,487.58 | 85.12 | +43.41% | |
| ₹4,642.90 | -0.84% | ₹1,76,600.99 | 82.55 | +31.42% | |
| ₹1,132.50 | -0.17% | ₹1,12,967.31 | 24.74 | +14.00% | |
| ₹2,059.40 | -0.47% | ₹1,11,271.90 | 102.63 | +134.89% | |
| ₹1,329.60 | +1.40% | ₹1,07,412.86 | 31.62 | -14.87% | |
| ₹1,240.00 | +0.86% | ₹1,03,500.36 | 32.26 | -1.93% | |
| ₹2,372.00 | -1.17% | ₹97,974.30 | 47.92 | -3.57% | |
| ₹1,684.60 | -1.31% | ₹96,928.16 | 26.40 | +49.04% | |
| ₹1,953.60 | +0.96% | ₹89,336.17 | 16.03 | -0.29% | |
| ₹2,265.30 | -0.78% | ₹63,932.35 | 35.82 | +16.81% | |
| ₹5,250.00 | +0.86% | ₹62,771.63 | 28.34 | -3.75% |
An investment of ₹10,000 made 4 years ago in Piramal Pharma is now worth
₹ 10,564.00
giving a profit of
₹ 564.00 (5.64%)
Note: Past profits do not guarantee future returns.
